CRISPR Therapeutics AG’s recent filing unveils that its Chief Executive Officer Kulkarni Samarth unloaded Company’s shares for reported $0.83 million on Dec 02 ’24. In the deal valued at $55.10 per share,15,000 shares were sold. As a result of this transaction, Kulkarni Samarth now holds 181,540 shares worth roughly $7.59 million.
Then, Kulkarni Samarth sold 30,000 shares, generating $1,668,678 in total proceeds. Upon selling the shares at $55.62, the Chief Executive Officer now owns 196,540 shares.
Before that, KASINGER JAMES R. sold 1,089 shares. CRISPR Therapeutics AG shares valued at $50,399 were divested by the General Counsel and Secretary at a price of $46.28 per share. As a result of the transaction, KASINGER JAMES R. now holds 62,597 shares, worth roughly $2.62 million.
Needham reiterated its CRISPR Therapeutics AG [CRSP] rating to a Buy in a research note published on August 06, 2024; the price target was $84. A number of analysts have revised their coverage, including Rodman & Renshaw’s analysts, who began to cover the stock in early August with a ‘”a Buy”‘ rating. Wolfe Research started covering the stock on February 15, 2024. It rated CRSP as “a Peer perform”.
Price Performance Review of CRSP
On Tuesday, CRISPR Therapeutics AG [NASDAQ:CRSP] saw its stock fall -0.10% to $41.81. Over the last five days, the stock has gained 0.72%. CRISPR Therapeutics AG shares have risen nearly 6.22% since the year began. Nevertheless, the stocks have fallen -33.50% over the past one year. While a 52-week high of $91.10 was reached on 01/22/25, a 52-week low of $36.52 was recorded on 01/13/25. SMA at 50 days reached $44.59, while 200 days put it at $50.49.
Levels Of Support And Resistance For CRSP Stock
The 24-hour chart illustrates a support level at 41.04, which if violated will result in even more drops to 40.26. On the upside, there is a resistance level at 42.49. A further resistance level may holdings at 43.16. The Relative Strength Index (RSI) on the 14-day chart is 47.98, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.15, which suggests price will go up in the next trading period. Percent R suggests that price movement has been low at 42.81%. Stochastics %K at 63.14% indicates the stock is a holding.
How much short interest is there in CRISPR Therapeutics AG?
A steep rise in short interest was recorded in CRISPR Therapeutics AG stocks on 2025-01-15, growing by 2.19 million shares to a total of 20.31 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-13 was 18.12 million shares. There was a rise of 10.81%, which implies that there is a positive sentiment for the stock.
